Tuesday, May 8, 2018

Job Opportunity: Post Doc Fellow - Novel Covalent Inhibitor Chemistry in Cambridge, United Kingdom

There is a great opportunity to work as an industrial postdoc at Astrazeneca on development of new covalent modifier drugs:

https://astrazeneca-us.jobs/cambridge-gbr/post-doc-fellow-novel-covalent-inhibitor-chemistry/BDCFE9F13ACE48CCB37468771C7B1233/job/

Preclinical characterization of EGT710, an oral non-peptidomimetic reversible covalent SARS-CoV-2 main protease inhibitor

Stephanie A. Moquin, Suresh B. Lakshminarayana, Kamal Kumar Balavenkatraman, Hilmar Schiller, Allison Claas, Barun Bhhatarai, Ioannis Loisio...